Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

60.94 -1.49 (-2.39%)

Streaming Delayed Price Updated: 11:27 AM EDT, Aug 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Breakfast News: A Conversation With Ionis CEO ↗

August 22, 2026

Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more.

Via The Motley Fool

Topics ETFs World Trade

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.

Via The Motley Fool

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? ↗

August 14, 2026

A drug that didn't meet expectations in a trial is to blame.

Via The Motley Fool

Ionis Pharmaceuticals (NASDAQ:IONS) Surges After Q2 Earnings Beat Estimates ↗

July 29, 2026

Via Chartmill

Topics Earnings

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Surge After Crushing Q1 Estimates and Raising Full-Year Guidance ↗

April 29, 2026

Via Chartmill

Ionis Pharmaceuticals (NASDAQ:IONS) Shows High Technical and Setup Ratings for Potential Breakout ↗

February 24, 2026

Via Chartmill

Ionis (IONS) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Revenue hit $268 million with 56% growth, while TRYNGOLZA sales accelerated.

Via The Motley Fool

Topics Earnings

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors? ↗

August 03, 2026

Insider holdings surged 34% through indirect acquisition, signaling confidence amid company's $8.8 billion valuation and RNA-therapy pipeline advancement.

Via The Motley Fool

Topics Regulatory Compliance

Ionis Pharmaceuticals Q2 Earnings Call Highlights ↗

July 29, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch...

Via MarketBeat

Topics Earnings

Cathie Wood Just Bet Big on This Biotech Stock ↗

July 18, 2026

Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing?

Via The Motley Fool

Topics ETFs

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗

July 13, 2026

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

Via MarketBeat

Which stocks are experiencing notable movement on Thursday? ↗

July 09, 2026

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

July 09, 2026

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

July 09, 2026

Via Chartmill

Discover the top movers in Thursday's pre-market session. ↗

July 09, 2026

Via Chartmill

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗

June 19, 2026

Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s....

Via InvestorPlace

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗

May 31, 2026

This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.

Via The Motley Fool

Topics Regulatory Compliance

Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts ↗

May 25, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare...

Via MarketBeat

Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference ↗

May 18, 2026

Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis...

Via MarketBeat

Ionis (IONS) Q1 2026 Earnings Call Transcript ↗

April 29, 2026

Ionis (IONS) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Ionis (IONS) Q4 2025 Earnings Transcript ↗

April 21, 2026

Ionis (IONS) Q4 2025 Earnings Transcript

Via The Motley Fool

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

March 26, 2026

The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which...

Via MarketMinute

When Insider Selling Is a Good Thing: 2 Stocks to Watch ↗

March 23, 2026

Ionis Pharmaceuticals and Waste Management insiders sell in early 2026, creating buying opportunities in their stocks while analysts raise price targets.

Via MarketBeat

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗

March 20, 2026

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗

March 20, 2026

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.

Via The Motley Fool

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗

March 15, 2026

HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.

Via The Motley Fool

Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally

March 11, 2026

In a significant milestone for precision medicine, Vertex Pharmaceuticals (NASDAQ:VRTX) emerged as the top performer in the S&P 500 on March 11, 2026, with its shares climbing 8.3%. The rally followed...

Via MarketMinute

Topics Stocks

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as...

Via Finterra

Topics Economy Intellectual Property

What a $20 Million Bet on a Stock Down 3% Signals for Investors ↗

February 03, 2026

UniFirst provides workplace uniforms and facility services via recurring contracts to a broad customer base in North America and beyond.

Via The Motley Fool

Topics Regulatory Compliance

Autoliv Stock Is Up 32% in a Year, But One Fund Just Cut $3.8 Million ↗

February 03, 2026

Autoliv develops advanced safety systems for global automakers, supplying airbags, seatbelts, and related technologies worldwide.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.